- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00913965
To Demonstrate the Relative Bioavailability of Atenolol Tablets
March 27, 2017 updated by: Sandoz
Bioavailability of Atenolol Tablets
To demonstrate the relative bioavailability of Atenolol tablets.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 50 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion Criteria:
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
Atenolol Tablets 100 mg (Cord Laboratories)
|
|
ACTIVE_COMPARATOR: 2
Atenolol Tablets 100 mg (Stuart Pharmaceutical)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bioequivalence based on AUC and Cmax
Time Frame: 11 days
|
11 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rudolph C. Cane, Jr., M.D., PharmaKinetics Laboratories Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 1989
Primary Completion (ACTUAL)
August 1, 1989
Study Completion (ACTUAL)
August 1, 1989
Study Registration Dates
First Submitted
June 2, 2009
First Submitted That Met QC Criteria
June 3, 2009
First Posted (ESTIMATE)
June 4, 2009
Study Record Updates
Last Update Posted (ACTUAL)
March 28, 2017
Last Update Submitted That Met QC Criteria
March 27, 2017
Last Verified
June 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Atenolol
Other Study ID Numbers
- 9103B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Atenolol Tablets 100 mg (Cord Laboratories)
-
SandozCompletedHypertension | Angina
-
SandozCompleted
-
Galapagos NVCompletedHealthyUnited Kingdom
-
Valenta Pharm JSCCompletedHealthyRussian Federation
-
Pain TherapeuticsNational Institute on Aging (NIA)Completed
-
SandozCompleted
-
British University In EgyptCompleted
-
SynAct Pharma ApsNBCD A/SCompletedRheumatoid ArthritisMoldova, Republic of
-
Sprout Pharmaceuticals, IncTerminatedDepression | Sexual Dysfunctions, PsychologicalUnited States